Oncobiologics
 | |
| | |
| Oncobiologics Inc. | |
|---|---|
| Type | Public |
| Industry | Pharmaceuticals |
| Headquarters | 7 Clarke Drive Cranbury, New Jersey 08512 USA |
| Key people | Pankaj Mohan, Ph.D. Kenneth M. Bahrt, M.D., F.A.C.R. Terrence Rugg, M.D. Lawrence A. Kenyon Stephen J. McAndrew, Ph.D. Scott A. Gangloff Elizabeth A. Yamashita Kogan Bao, Ph.D. [1] |
| Investors | Not Known |
| Products | ONS-3010 ONS-1045 |
| Revenue | $5M (2015) [2] |
| Number of employees | 50 |
Oncobiologics is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. The company is focused on monoclonal antibodies (mAbs), in the disease areas of immunology and oncology. Oncobiologics is establishing a fully integrated in-house development and manufacturing capabilities platform to address the numerous complex technical and regulatory challenges in developing and commercializing mAb biosimilars.
The company was founded by Pankaj Mohan, Ph.D., who previously served as head of Business Operations and Portfolio Management of Biologics Process and Product Development at Bristol-Myers Squibb Company. Dr. Mohan also served as a Director of Bioprocess Engineering at Genentech, Inc.
Contents
[hide]Product Pipeline[edit | edit source]
Oncobiologics is currently developing a portfolio of eight mAb biosimilars. The company’s most advanced assets, ONS-3010 (a biosimilar of Humira®) and ONS-1045 (a biosimilar of Avastin®) have both successfully completed Phase I trials. The company has initiated Phase 3 preparatory activities for ONS-3010 and ONS-1045.
